Cormorant Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cormorant Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-125,000	Closed	-$9.97M	–	54
2017 Q2	$9.97M	Buy	+125,000	New	+$7.99M	1.65%	21
2016 Q4	–	Sell	-126,120	Closed	-$8.55M	–	79
2016 Q3	$8.55M	Sell	126,120 -74,235	-37%	-$5.24M	0.94%	35
2016 Q2	$11.1M	Sell	200,355 -44,645	-18%	-$2.81M	1.58%	24
2016 Q1	$15.4M	Hold	245,000	–	–	2.32%	12
2015 Q4	$23.1M	Buy	245,000 +105,000	+75%	+$9.74M	2.76%	11
2015 Q3	$11.3M	Hold	140,000	–	–	1.8%	19
2015 Q2	$16.8M	Buy	+140,000	New	+$16.7M	2.23%	13
2014 Q4	–	Sell	-50,000	Closed	-$3.9M	–	72
2014 Q3	$3.9M	Hold	50,000	–	–	0.8%	34
2014 Q2	$3.16M	Hold	50,000	–	–	0.84%	41
2014 Q1	$3.36M	Sell	50,000 -200,000	-80%	-$15.5M	0.77%	37
2013 Q4	$16.1M	Buy	+250,000	New	+$14.9M	4.67%	10

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cormorant Asset Management's ALNY Position: Q3 2017 in Review

Cormorant Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2017, closing a stake of 125,000 shares — an estimated $9.97M sold.

Cormorant Asset Management first reported a position in ALNY in Q4 2013 and held it in 11 quarters. The position peaked at $23.1M in Q4 2015. 236 funds tracked by Wall St. Rank hold ALNY as of Q3 2017.

Cormorant Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Cormorant Asset Management sold 125,000 Alnylam Pharmaceuticals shares in Q3 2017, an estimated $9.97M.
Cormorant Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 11 quarters.
Cormorant Asset Management's Alnylam Pharmaceuticals position peaked at $23.1M in Q4 2015.
236 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2017.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.